On October 24, a delegation from Beijing Daxing District visited Shenzhen Cell Valley for inspection and exchange. The delegation included Cai Xiaojun, Member of the Standing Committee of the Daxing District Committee and Head of the United Front Work Department; Zheng Qingyu, Deputy Head of the District United Front Work Department and Party Secretary of the District Federation of Industry and Commerce; Yin Shaoyi, Director of the District Ethnic and Religious Affairs Office; Han Feng, Party Member and Vice Chairman of the District Federation of Industry and Commerce; Wang Erbao, Deputy Head of the District United Front Work Department; Peng Qiuyan, Director of the Project Promotion Department of the District Investment Promotion Service Center; Liu Jingbin, Officer of the District Committee Office; and Zhang Xiaotian, Secretary-General of the District Young Entrepreneurs Association. Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley; Wang Jianxun, Chief Scientist; Wei Zheng, Assistant to the Chairman; Luan Zhishi, Director of the General Administration Office; and Sun Rui, Head of Market Development, extended a warm welcome and held symposium discussions.

Accompanied by Chairman Professor Shi Yuanyuan, the Daxing District leaders toured Shenzhen Cell Valley's smart exhibition hall, gaining a detailed understanding of the company's core technology products, overall development, and planned construction. They fully affirmed the company's achievements in innovative services, research investment, and achievement translation in emerging industries.

During the symposium, Chairman Professor Shi Yuanyuan expressed sincere gratitude for the visit and care of the Beijing Daxing District leaders, and reported to them on Shenzhen Cell Valley's rapid development and the advantages of its breakthrough technology—GMP industrial-scale production of retroviral vectors—as well as the unique value it provides in offering standardized, professional services that link the upstream and downstream of the cell and gene therapy industry. He noted that Beijing, as a key for the Cell Valley team's strategic development, will fully absorb research talent in the future to contribute to the development of the cell therapy industry. The Daxing District leaders stated that they would continue to follow the development of our wholly-owned subsidiary Beijing Jing-Shen Cell Valley. As a strong backing for the company's development, Daxing District will increase efforts to advance project construction and provide a series of precise services including financial support, resource matching, platform co-development, and talent attraction, creating a favorable innovation and entrepreneurship environment, strengthening development confidence, and jointly building a new ecosystem for cell and gene therapy with Shenzhen Cell Valley.

This meeting advanced the construction progress of Jing-Shen Cell Valley. Positive communication with relevant government departments can effectively and precisely resolve issues, jointly supporting progress in medical research.